Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset RMD

Coverage 92,268 Raw stories ingested 7,951 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,727 Assets with fetched stories

Cryptocurrencies BTC 4,245 ETH 3,075 SOL 1,750 XRP 1,686 USDC 965 HYPE 822

Stocks SPCX 879 MU 723 NVDA 684 MSFT 557 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,679 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 23s ago
FMP Forex News Fetch every 5 min 1m ago
CoinGecko News Fetch every 5 min 1m ago
FIO Stock News Fetch every 10 min 23s ago
Patria Stock News Fetch every 10 min 23s ago
Editorial rewrite Rewrite every minute 23s ago
Asset sync Assets every 1 hour 30m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-21 13:06 4d ago Published 2026-07-21 04:01 5d ago	Baader Bank snížila podíl v ResMed o 61,7 % Baader Bank Aktiengesellschaft v 1. čtvrtletí snížila podíl v ResMed o 61,7 % na 4 768 akcií. Hodnota držby činila 1,045 milionu USD. RMD ResMed	FMP Stock News	72
Original source text Posted by Defense World Staff on Jul 21st, 2026 Baader Bank Aktiengesellschaft decreased its stake in shares of ResMed Inc. (NYSE:RMD – Free Report) by 61.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,768 shares of the medical equipment provider’s stock after selling 7,696 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in ResMed were worth $1,045,000 as of its most recent SEC filing. Several other large investors also recently added to or reduced their stakes in RMD. Jones Financial Companies Lllp raised its stake in shares of ResMed by 52.6% during the first quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock valued at $645,000 after acquiring an additional 994 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in ResMed in the second quarter worth approximately $389,000. Brown Advisory Inc. increased its holdings in ResMed by 17.8% during the 2nd quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 240 shares during the period. Cresset Asset Management LLC purchased a new position in ResMed during the 2nd quarter worth $206,000. Finally, Alliancebernstein L.P. raised its position in ResMed by 24.2% during the 2nd quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock valued at $73,808,000 after purchasing an additional 55,790 shares in the last quarter. 54.98% of the stock is owned by hedge funds and other institutional investors. ResMed Trading Down 0.2% NYSE RMD opened at $198.55 on Tuesday. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06. The firm has a market cap of $28.80 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 1.19 and a beta of 0.78. The company has a 50 day moving average price of $199.39 and a 200 day moving average price of $226.21. ResMed Inc. has a 52 week low of $180.26 and a 52 week high of $293.81. ResMed (NYSE:RMD – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.07. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The company had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $1.42 billion. During the same period last year, the firm earned $2.37 earnings per share. ResMed’s revenue was up 10.8% compared to the same quarter last year. As a group, sell-side analysts forecast that ResMed Inc. will post 11.13 EPS for the current fiscal year. ResMed Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Thursday, May 14th. ResMed’s dividend payout ratio is currently 23.14%. Analyst Upgrades and Downgrades Several brokerages have weighed in on RMD. Mizuho lowered their target price on ResMed from $235.00 to $220.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Evercore set a $255.00 price target on ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. The Goldman Sachs Group restated a “buy” rating on shares of ResMed in a report on Wednesday, July 1st. Royal Bank Of Canada lowered shares of ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 price objective for the company. in a research note on Thursday. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $230.00 target price (down from $286.00) on shares of ResMed in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $250.00. Get Our Latest Analysis on RMD Insider Buying and Selling at ResMed In related news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at $101,893,036.65. The trade was a 1.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 14,973 shares of company stock valued at $3,096,067. 0.65% of the stock is owned by company insiders. ResMed Company Profile (Free Report) ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide. ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders. Further Reading Five stocks we like better than ResMed The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter. « PREVIOUS HEADLINEBank of New York Mellon Corp Trims Position in Chewy $CHWY NEXT HEADLINE »Baader Bank Aktiengesellschaft Buys 4,529 Shares of Citigroup Inc. $C
	Saved 2026-07-10 20:17 15d ago Published 2026-07-10 13:56 15d ago	ResMed prodá MatrixCare a zaměří se na klíčové oblasti ResMed prodá MatrixCare společnosti Frazier Healthcare Partners, aby se více soustředil na spánek, dýchání a propojenou domácí péči. Uzavření transakce se očekává v 1. čtvrtletí fiskálního roku 2027. RMD ResMed	FMP Stock News	86
Original source text Key Takeaways Resmed will sell MatrixCare to Frazier Healthcare Partners, with closing expected in fiscal Q1 2027.The divestiture enables Resmed to focus its investments on sleep, breathing and connected home-based care.Brightree and MEDIFOX DAN remain central to Resmed's connected care strategy and are not part of the deal. Resmed (RMD - Free Report) has entered into a definitive agreement to sell its MatrixCare business to private equity firm Frazier Healthcare Partners. The divestiture aligns with the company's long-term strategy to sharpen its focus on higher-growth opportunities across sleep health, breathing health and connected home-based care. The transaction is expected to close in the first quarter of fiscal 2027, subject to regulatory approvals and customary closing conditions. From an investor's perspective, the divestiture underscores Resmed's disciplined capital allocation strategy and reinforces its commitment to businesses with stronger long-term growth potential and higher scalability. By streamlining its portfolio and reallocating resources toward innovation in its core connected care ecosystem, the company is positioning itself to strengthen its competitive edge and drive sustainable value creation, while enabling MatrixCare to pursue growth under an owner dedicated to the long-term care software market. Likely Trend of RMD Stock Following the NewsShares of RMD have traded flat since the announcement on July 7. In the year-to-date period, shares of the company have lost 13.5% compared with the industry’s 21.8% decline. The S&P 500 increased 9.5% in the same time frame. The divestiture is likely to strengthen Resmed's long-term growth profile by enabling the company to concentrate investments on its core sleep and breathing care franchises, where it enjoys strong market leadership and significant innovation opportunities. The transaction should also enhance capital allocation flexibility, allowing Resmed to accelerate product development, expand its AI-powered digital health offerings and scale its connected home-care ecosystem. By exiting a non-core software business, the company can simplify operations, improve strategic focus and better position itself to capitalize on the growing global demand for home-based healthcare and sleep therapy solutions. RMD currently has a market capitalization of $29.86 billion. Image Source: Zacks Investment Research More on the NewsThe transaction covers the entire MatrixCare business, including Healthcare First, Citus and its home health and hospice software solutions, which together serve more than 15,000 providers across skilled nursing, senior living, life plan communities, home health and hospice settings. However, the deal does not include Resmed's other healthcare software businesses, Brightree in the United States and MEDIFOX DAN in Germany, both of which remain integral to the company's connected care strategy. Management stated that MatrixCare will continue operating as part of Resmed until the transaction closes, with no disruption to customer service or support. Resmed also noted that it will provide additional details regarding the transaction's financial impact in its fiscal fourth-quarter 2026 regulatory filings and has furnished a Form 8-K with the SEC outlining the agreement. For Frazier Healthcare Partners, the acquisition represents a strategic investment in the growing post-acute care technology market. The private equity firm, which focuses exclusively on healthcare investments, plans to invest aggressively in product innovation to strengthen MatrixCare's capabilities and support evolving customer needs across long-term and post-acute care settings. Resmed believes the new ownership structure will allow MatrixCare to pursue its long-term growth ambitions with a dedicated strategic focus, while enabling it to devote greater attention and resources to advancing AI-powered digital health solutions, cloud-connected medical devices and other technologies aimed at improving sleep, breathing and home-based healthcare outcomes. Favorable Industry Prospect for RMDGoing by the data provided by Grand View Research, the global home healthcare market size was valued at $485.3 billion in 2025 and is projected to grow from $504.8 billion in 2026 to $1015.8 billion by 2033, at a CAGR of 10.5% from 2026 to 2033. The market is driven by rising demand for cost-effective alternatives to curb rising healthcare costs and the growing penetration of the virtual and remote care industry. A Recent Development by RMDRecently, Resmed completed the acquisition of Noctrix Health to broaden its clinical sleep health portfolio with the addition of Nidra Tonic Motor Activation Therapy, an FDA De Novo-classified, non-invasive treatment for moderate-to-severe Restless Legs Syndrome RLS. The deal expands Resmed's presence into one of the most prevalent sleep disorders, complementing its core sleep therapy business while enhancing its ability to offer innovative, drug-free treatment options. The acquisition is also expected to accelerate patient access to the therapy by leveraging Resmed's global commercial and distribution capabilities. RMD’s Zacks Rank & Key PicksCurrently, RMD carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , West Pharmaceutical (WST - Free Report) and Pacific Biosciences of California (PACB - Free Report) . Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), has an estimated earnings growth rate of 5.1% for 2026. VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.9%. You can see the complete list of today’s Zacks #1 Rank stocks here. Veracyte’s shares have gained 33.3% against the industry’s 14.2% decline in the year-to-date period. West Pharmaceutical, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. West Pharmaceutical’s shares have gained 28.5% against the industry’s 1.2% decline in the year-to-date period. Pacific Biosciences of California, currently carrying a Zacks Rank #2, has an estimated earnings growth rate of 22.6% for 2026. PACB’s earnings beat estimates in each of the trailing four quarters, the average surprise being 29.8%. Pacific Biosciences’ shares have lost 19.8% compared with the industry’s 14.2% decline in the year-to-date period.
	Saved 2026-07-07 22:45 18d ago Published 2026-07-07 16:30 18d ago	Resmed prodá MatrixCare firmě Frazier Healthcare Resmed uzavřel definitivní dohodu o prodeji divize MatrixCare firmě Frazier Healthcare Partners. Transakce má být dokončena v prvním čtvrtletí fiskálního roku 2027. RMD ResMed	FMP Stock News	88
Original source text SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed’s 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare. The divestiture also strengthens Resmed’s ability to reallocate capital and resources toward innovation, operational scale and long-term value creation across its connected, home-based care ecosystem. MatrixCare provides software solutions to more than 15,000 providers and supports skilled nursing, senior living and long-term care, life planning communities and home health and hospice care. “Today’s announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth,” said Mick Farrell, Chairman and CEO of Resmed. “By focusing on areas where we see the greatest opportunity for sleep health innovation and impact, we are strengthening our ability to deliver life-changing health technologies, improve patient outcomes and create value for our stakeholders. We are confident MatrixCare and its affiliated businesses will continue to support team members and drive growth under new ownership with a dedicated focus on the long-term care market.” “Frazier has spent several years evaluating the post-acute care technology sector and believes MatrixCare has established itself as a leading platform serving skilled nursing, senior living and home health and hospice providers,” said Ryan Lucero, General Partner at Frazier Healthcare Partners. “We are thrilled to partner with the MatrixCare team and plan to invest aggressively in product innovation to help providers deliver better outcomes as the post-acute care landscape continues to evolve.” The transaction includes MatrixCare and related software offerings historically sold under the MatrixCare brand, including Healthcare First, Citus and home health and hospice solutions (collectively defined as the “MatrixCare business”). It excludes Resmed’s other software businesses, Brightree in the U.S. and MEDIFOX DAN in Germany. The transaction is expected to close during the first quarter of Resmed’s fiscal year 2027, subject to required regulatory approvals and customary closing conditions. Until closing, MatrixCare will continue to operate as part of Resmed, with no changes to customer service or support. Resmed is providing additional information regarding this transaction through a Form 8-K furnished with the U.S. Securities and Exchange Commission (SEC). Supplementary materials related to this press release are available on Resmed’s Investor Relations website at investor.resmed.com. Resmed will provide further updates regarding the financial impact of the transaction in its regulatory filings for the fourth quarter of its fiscal year 2026, consistent with regulatory requirements. About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed. About Frazier Healthcare Partners Founded in 1991, Frazier Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. Since its inception, Frazier has raised over $11 billion of capital for private funds and co-investment opportunities and has invested in more than 200 companies over 35 years. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier is headquartered in Seattle, WA, with an office in New York City, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier, visit www.frazierhealthcare.com/home. For Media Brad Lotterman [email protected] [email protected] For Investors Salli Schwartz [email protected] [email protected]